While immuno-oncology remains our primary development focus, collaborations with partners like Leidos and the University of Edinburgh’s Center for Immunity, Infection and Evolution (CIIE), allow us to expand the use and potential value in infectious diseases.
The breadth and depth of our platform can enable us to target some of the most hard-to-address diseases in this space, including public health threats and indications with limited or no treatment options, such as RSV, virulent malaria, bioterrorism threats and the Zika virus.
Recent progress includes:
Our delivery platform has been shown in multiple studies to produce strong, high-quality immune responses with a tolerable safety profile across a range of infectious diseases, and to have the potential to produce these specific and sustained immune effects from a single dose.
Other novel characteristics of agents based on our platform, including the flexibility to work with almost any antigen or adjuvant and the scalability of off-the-shelf manufacturing, have the potential to eliminate drug development barriers, bringing stronger treatments to markets faster in areas of high unmet medical needs.